https://www.selleckchem.com/products/deutenzalutamide.html [This corrects the article DOI 10.1002/agm2.12114.].As percentages of elderly people rise in many societies, age-related diseases have become more prevalent than ever. Research interests have been shifting to delaying age-related diseases by delaying or reversing aging itself. We use metformin as an entry point to talk about the important molecular and genetic longevity-regulating mechanisms that have been extensively studied with it. Then we review a number of observational studies, animal studies, and clinical trials to reflect the clinical potentials of the mechanisms in lifespan extension, cardiovascular diseases, tumors, and neurodegeneration. Finally, we highlight remaining concerns that are related to metformin and future anti-aging research. Since the outbreak of coronavirus disease 2019 (COVID-19), clinical features have been analyzed in detail. However, coagulopathy in elderly COVID-19 patients has been scarcely reported. Coagulation parameters of 189 patients with COVID-19 in Tongji hospital were retrospectively analyzed among age groups. Patients were divided into 2 groups older group (≥65years, n=87) and younger group (<65years, n=102). The proportion of patients with elevated fibrinogen (79.0% vs 59.6%, =.005) and D-dimer (78.0% vs 55.2%, =.001) shows the significant difference between the groups. The elderly patients revealed significantly longer prothrombin time (14.0 [13.4-14.4]s vs 13.6 [13.2-14.1]s, =.026), higher D-dimer (1.00 [0.5-1.9] μg/mL vs 0.6 [0.3-1.6] μg/mL, =.013) and fibrinogen (5.2 [4.1-6.2] g/L vs 4.4 [3.4-5.7] g/L, =.004) levels, compared to the younger group. A positive correlation was observed between the coagulation parameters and inflammatory markers including high-sensitivity C-reactive protein and interleukin-6 ( <.05). The hypercoagulable state is more common in elderly COVID-19 patients, and coagulopathy is associated with excessive systemic inflammation. The hypercoa